Medical cannabis in Quebec: who can prescribe it and how to access it

Medical cannabis has been legal in Canada since 2001 - almost twenty years before the legalization of recreational cannabis in 2018. Yet it remains one of the treatments least understood by the patients who could benefit from it, and one of the subjects on which clinicians themselves are most reluctant to make a clear commitment.

This guide answers the concrete questions posed by patients considering medical cannabis in Quebec in 2026: how it differs from recreational cannabis, for which conditions the clinical data is strongest, how the prescription process works at Clinique Omicron, what insurance covers treatment and under what conditions, and what real risks to be aware of before starting.

The legalization of recreational cannabis in October 2018 has created persistent confusion in the minds of many patients: if cannabis is legal over the counter, why go through a doctor? The answer touches on real, concrete legal, medical and financial differences.

Regulatory framework

Medical cannabis in Canada is governed by Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPMR) - a regulatory framework distinct from that governing recreational cannabis sold in Société québécoise du cannabis (SQDC) boutiques. This regulatory framework imposes strict obligations on authorized producers: documented quality controls, certified THC and CBD content per batch, tested and attested absence of contaminants, full product traceability.

Medicinally-derived cannabis is produced by Health Canada-licensed producers and delivered directly to the patient by courier - bypassing the SQDC. Patients are not limited to the formats and strengths available at recreational retail - they can access formulations, strengths and routes of administration tailored to their specific clinical profile.

Legal possession of medical cannabis is not limited by the caps that apply to recreational cannabis - a registered patient with a valid medical document can possess the amount prescribed by their doctor, which can exceed the recreational possession limit of 30 grams.

Quality and traceability

Medical cannabis purchased from a producer authorized by Health Canada is subject to pharmaceutical quality standards - each batch is tested for cannabinoid content, pesticides, heavy metals, mold and bacteria. Patients receive a certificate of analysis for each batch, enabling them to verify exactly what they are consuming.

Recreational cannabis sold at SQDC is also subject to regulatory quality controls, but the medical setting offers more rigorous traceability and documentation - particularly relevant for patients who use cannabis in a documented therapeutic context and for whom consistency of concentrations between batches is clinically important.

Dosage and medical support

Medically obtained cannabis is prescribed within the framework of a therapeutic relationship with a physician - which means prior assessment of the indication, discussion of the appropriate route of administration and format, cautiously initiated dosing with gradual adjustments, and documented medical follow-up. This clinical framework reduces the risk of inappropriate doses, undetected drug interactions, and aggravation of contraindicated psychiatric conditions.

Repayment - the decisive advantage

This is often the most decisive difference in a patient's choice between medical and recreational cannabis: medical cannabis can be reimbursed by certain private insurance companies and compensation plans - Veterans Affairs Canada, CNESST, SAAQ - under certain conditions. Recreational cannabis, purchased from SQDC, is never reimbursable. This distinction is discussed in detail in the section on reimbursement.

Conditions that can be treated with medical cannabis

Medical cannabis is not a panacea, and clinical data are not equally robust for all the conditions cited. Here is an honest presentation of the state of the data for the most common indications.

Chronic pain

Chronic pain - particularly neuropathic pain - is the indication for which the body of clinical data on medical cannabis is the strongest and most consistent. Meta-analyses published in leading journals document modest but statistically significant analgesic efficacy for peripheral and central neuropathic pain, pain associated with multiple sclerosis, and chronic non-cancer pain refractory to conventional treatments.

Cannabis generally doesn't eliminate pain completely - it reduces it by a level sufficient to improve daily functioning, sleep, and quality of life. This is a realistic therapeutic goal, distinct from cure, and clinically relevant for patients whose pain persists despite several lines of conventional treatment.

The most well-documented indication remains neuropathic pain - pain related to injury or dysfunction of the nervous system, such as diabetic neuropathy, post-herpetic neuralgia, phantom pain, and pain associated with neurological pathologies. Chronic nociceptive pain responds more variably.

Insomnia associated with a medical condition

Insomnia is frequently reported as an indication by patients who consult for medical cannabis - and clinical data, though less robust than for neuropathic pain, suggest efficacy on sleep latency and nocturnal arousals, mainly via the effects of CBD and balanced CBD:THC ratios.

The important clinical nuance is that medical cannabis is more indicated for insomnia associated with an underlying medical condition - chronic pain that prevents falling asleep, PTSD with nightmares and nocturnal hypervigilance, nocturnal spasticity - than for isolated primary insomnia, for which cognitive-behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment.

The chronic use of THC for sleep also raises the question of the impact on long-term sleep architecture - THC reduces REM sleep, which may have implications for memory consolidation and emotional processing. This point is worth discussing during the medical consultation.

PTSD - post-traumatic stress disorder

PTSD is an indication for which clinical interest in medical cannabis has grown significantly in recent years, driven in particular by data from the veterans programs of the Canadian Armed Forces and Veterans Affairs Canada - which cover medical cannabis for veterans with documented PTSD.

Symptoms for which the data are most encouraging include nightmares and sleep disturbances, hypervigilance and excessive responses to stimuli, and chronic anxiety associated with PTSD. Medical cannabis in this indication is generally used to complement - not replace - evidence-based psychotherapies for PTSD, including cognitive processing therapy (CPT) and eye movement desensitization (EMDR).

Chemotherapy-related nausea and vomiting

This is one of the best-documented historical indications for cannabinoids - synthetic THC-based drugs (dronabinol, nabilone) have been approved by Health Canada since the 1980s for chemically-induced nausea and vomiting refractory to conventional antiemetics. Nabilone (Cesamet) is available on prescription in Canada for this indication, and is conditionally covered by the RAMQ.

Medical cannabis in its plant or oil form represents a therapeutic option for patients who cannot tolerate standard antiemetics or who are looking for a complementary option to improve their quality of life during oncology treatment. Consultation with the oncologist is recommended in parallel to ensure no interaction with the chemotherapy protocol.

Spasticity - multiple sclerosis and spinal cord injury

Spasticity associated with multiple sclerosis (MS) and spinal cord injury is an indication recognized by several medical associations and well documented in the literature. Sativex - an oral spray with a THC:CBD 1:1 ratio - is approved by Health Canada specifically for moderate to severe spasticity in MS refractory to conventional treatments. The use of medical cannabis in other formulations for this indication follows the same therapeutic logic.

Other conditions - more limited data

Several other conditions are frequently mentioned in connection with medical cannabis - drug-resistant epilepsy (the data for CBD is strong, especially for certain pediatric syndromes, and Epidiolex - pharmaceutical CBD - is approved for this indication), fibromyalgia, chronic inflammatory bowel disease, and anxiety. For some of these conditions, the data are promising but still insufficient for firm recommendations. Your doctor will assess whether your specific clinical picture represents a medically justified indication.

Prescription process at Clinique Omicron

The term «prescription» for medical cannabis is actually a misuse of legal language - strictly speaking, the doctor issues a "prescription" for the drug. medical document authorizing the patient to register with a producer authorized by Health Canada, rather than a conventional pharmaceutical prescription. The actual process involves several distinct steps.

Initial medical consultation

The first step is a full medical consultation at Clinique Omicron, either face-to-face in Brossard or Saint-Hubert, or via telemedicine for patients eligible for remote evaluation.

As with all Clinique Omicron consultations, a nurse performs a triage prior to the medical consultation - taking a full medical history, listing current medications, nature and duration of symptoms, treatments already tried for the presenting condition and their results. This structured clinical triage enables the doctor to arrive at the consultation with a clear picture and optimize the time available for assessment and discussion.

During the consultation, the doctor assesses whether your condition represents a medically justified indication for medical cannabis - based on available clinical data and Canadian Medical Association guidelines. He documents the conventional treatments already tried and their results - medical cannabis is generally indicated for conditions refractory to first-line treatments rather than as a first-line treatment. It assesses contraindications and risk factors specific to your situation. He discusses realistic expectations, available forms, routes of administration and titration approach.

Health Canada form and medical document

If the doctor concludes that medical cannabis is medically justified for your situation, he completes the medical document in accordance with Health Canada regulatory requirements. This document indicates your identity, the authorized daily quantity in grams of dried cannabis equivalent, and the period of validity of the document - generally one year, renewable.

The daily amount listed is a medical decision based on your condition, risk profile and estimated therapeutic dosage - it is not an authorization to consume that amount daily, but a regulatory limit that defines how much you can legally hold.

Registration with an authorized producer

With the medical document in hand, you register directly with the Health Canada-authorized producer of your choice - an administrative process you do yourself, usually online at the producer's website. Major authorized producers in Canada include Tilray, Aurora, MedReleaf, Aphria, and many others. Each producer offers a different catalog of products - dried flowers in different varieties, oils, capsules, extracts - with varying THC and CBD concentrations.

Your Clinique Omicron doctor can direct you to the producers whose catalog corresponds to your therapeutic profile, and advise you on the formats and concentrations best suited to your condition and personal situation. The cannabis is then delivered directly to your address by secure mail.

Medical follow-up

Medical cannabis is not a treatment that is initiated and then left unsupervised. Regular medical follow-up - usually at one month after the start of treatment, then at three and six months - enables us to assess efficacy on target symptoms, adjust the dose if necessary, detect side effects, and periodically re-evaluate the indication. The medical document must be renewed - usually on an annual basis - which requires regular medical reassessment.

Insurance reimbursement

Reimbursement of medical cannabis by employer group insurance has progressed significantly in Canada since 2018 - a growing number of plans now conditionally cover medical cannabis, although coverage remains far from universal.

Plans that cover medical cannabis generally require several cumulative conditions: a valid medical document signed by a licensed physician documenting the therapeutic indication, registration with a producer licensed by Health Canada, a documented medical diagnosis as part of the conditions covered by the plan, and sometimes demonstration that conventional treatments have been tried and found insufficient.

Insurance companies with reimbursement programs for medical cannabis in Canada include Sun Life, Manulife, Great-West Life (Canada Life), Desjardins, and many others - each with its own criteria and limits. Reimbursement amounts range from 1,500 $ to 6,000 $ per year, depending on the plan, with limits per gram or per day.

The practical approach: contact your insurer or your employer's human resources department to verify whether your plan includes coverage for medical cannabis and what documentation is required for the claim. Clinique Omicron provides a medical letter and the necessary clinical documentation to support your insurance claim.

Veterans Affairs Canada

The Veterans Affairs Canada (VAC) program covers medical cannabis for eligible veterans, with reimbursement of up to 3 grams per day for covered conditions - including PTSD, chronic pain, and many other conditions associated with military service. Documentation requirements include a medical document from a licensed physician and registration with a licensed producer. If you're a veteran, this coverage is significant and worth exploring with your doctor.

CNESST and SAAQ

The Commission des normes, de l'équité, de la santé et de la sécurité du travail (CNESST) and the Société de l'assurance automobile du Québec (SAAQ) cover medical cannabis in specific circumstances related to occupational injuries or motor vehicle accidents, respectively - when treatment is medically justified for the after-effects of these events. Coverage is granted on a case-by-case basis, based on medical records.

RAMQ

The RAMQ does not cover medical cannabis as such - herbal or oily medical cannabis products are not listed on the reimbursed drug formulary. Nabilone (Cesamet), a synthetic THC on prescription, is covered by RAMQ under specific criteria for refractory chemo-induced nausea and vomiting - but it is a pharmaceutical drug distinct from medical cannabis as defined by Health Canada's program.

Side effects and medical precautions

Balanced information on medical cannabis includes an honest presentation of the risks - not to discourage patients who have a medically justified indication, but so that the therapeutic decision is informed.

Acute side effects of THC

THC - tetrahydrocannabinol - is the psychoactive cannabinoid responsible for the high. In a medical context, therapeutic doses are generally much lower than recreational doses, and the aim is to obtain an analgesic or anxiolytic effect without marked intoxication - but THC-related adverse effects can occur, particularly at the start of treatment or when dosage adjustments are made.

The most common effects include sedation and drowsiness - relevant for patients who have to drive or operate machinery, and imposing a strict rule: do not drive within hours of consuming THC-containing cannabis. Dizziness, tachycardia and orthostatic hypotension may occur, particularly in the elderly and in patients with cardiovascular pathologies. Dry mouth and increased appetite are common. Concentration difficulties and short-term cognitive disturbances are expected with THC in high doses.

Paradoxical anxiety and panic episodes can be triggered by THC, particularly at high doses or in patients with a history of anxiety disorders - this is one of the reasons why gradual titration from low doses is a fundamental principle of medical cannabis prescribing.

Long-term effects

Regular and prolonged use of cannabis with a high THC content is associated with documented risks that must be taken into account in the therapeutic decision.

Visit dependency - a cannabis use syndrome with formal diagnostic criteria - develops in around 9 % of regular users, with a higher frequency in people who start using in adolescence and in those with a history of dependence on other substances. Medical cannabis dependence is a clinical reality to be monitored, not a taboo to be ignored.

Effects on long-term cognition - working memory, processing speed, executive functions - are documented with chronic use of high-THC cannabis, with partial recovery on cessation. The impact is most marked in people who start before the end of brain development, i.e. before the age of around 25.

The association between cannabis use and increased risk of psychosis and schizophrenia is documented in the epidemiological literature - the risk is proportional to THC content, frequency of use, and individual genetic vulnerability. This association is the main reason why a personal or family history of psychosis is a formal contraindication to THC-containing medical cannabis.

Drug interactions

Cannabinoids are metabolized by the CYP450 enzyme system - mainly CYP3A4 and CYP2C9 - creating the potential for pharmacokinetic interactions with many commonly prescribed drugs.

Visit anticoagulants, Cannabis can increase the anticoagulant effect, requiring closer monitoring of INR at the start of treatment. The immunosuppressants such as tacrolimus and cyclosporine, can have their concentrations altered by cannabis - an interaction particularly relevant to transplant patients. The antidepressants and anxiolytics may have additive pharmacodynamic interactions with cannabis. The benzodiazepines and opioids used in combination with cannabis can produce additive respiratory depression in high doses.

A complete list of your current medications must be provided to your doctor during the medical cannabis consultation - this medication review is a non-negotiable clinical step.

Contraindications

Certain contraindications are absolute - medical cannabis containing THC is formally contraindicated in the following situations: personal history of psychosis, schizophrenia or bipolar disorder with psychotic episodes, pregnancy and breastfeeding, history of severe allergic reaction to cannabis, under 25 years of age except for very specific indications under specialized supervision.

Other contraindications are relative and need to be assessed on a case-by-case basis: history of dependence on other substances, significant cardiovascular pathologies including heart failure and arrhythmia, severe respiratory pathologies for inhaled forms, history of severe major depressive episodes.

Safe dosing - the fundamental principle

The principle of progressive titration - «start low, go slow» - is the foundation of all medical cannabis prescribing. The minimum effective dose is the therapeutic goal, not the maximum tolerated dose. For cannabis-naive patients, initial doses are very low - just a few milligrams of THC - gradually increased according to tolerance and clinical effect, over several weeks to months.

The route of administration has a direct influence on treatment safety. Oral oils and capsules have slow absorption and a gradual onset of action - peak plasma levels are reached in 1-3 hours, facilitating titration and reducing the risk of accidental overdose. Inhalation - vaporization rather than combustion in the medical context - produces a rapid onset of action in a matter of minutes, enabling better dose-response adjustment in real time, but requiring more experience to avoid excessive consumption.

Frequently asked questions

Do I need a prescription to obtain medical cannabis in Quebec?

Technically, this is not a prescription in the conventional pharmaceutical sense, but a medical documentissued by a licensed physician and compliant with Health Canada requirements. This document authorizes you to register with a licensed producer and receive medical cannabis by mail. Without this medical document signed by a physician, you cannot access Health Canada's medical cannabis program. Prior medical consultation is mandatory - it's not an administrative formality, but an actual clinical evaluation.

Can medical cannabis replace my current medications?

In the vast majority of cases, medical cannabis is used to treat complementary and not as a replacement for medication already prescribed - particularly for complex conditions such as chronic pain, PTSD, or spasticity. In some cases, an improvement in symptoms with cannabis may make it possible to reduce doses of other medications - notably opioids for chronic pain - but this modification should never be done on its own. Any change in your medication regimen should be discussed and supervised by your doctor.

Can my family doctor refuse to prescribe me medical cannabis?

Yes - no doctor is legally obliged to issue a medical document for cannabis. Some family physicians are reluctant to engage in this practice due to lack of training or out of principle. If your family doctor does not prescribe medical cannabis, you can consult a Clinique Omicron physician who will evaluate your file and determine if you are a suitable candidate.

Can I drive after taking my medical cannabis?

No, if your treatment contains THC and you have recently taken it. THC-impaired driving is a criminal offence in Canada, identical to driving under the influence of alcohol. The time after which it is safe to drive depends on the dose, the route of administration, your individual tolerance, and the format consumed - there is no precise universal rule. In medical practice, it is advisable to avoid driving within hours of consuming THC-containing cannabis, and to have an explicit discussion with your doctor about driving as part of your treatment.

Does CBD-only medical cannabis carry the same risks?

CBD - cannabidiol - is the non-psychoactive cannabinoid in cannabis, with a significantly more favorable safety profile than THC. It produces no psychoactive effects, is not associated with the psychiatric risks of THC, and does not cause driving impairment. Products based on pure CBD or with a high CBD/minimal THC ratio have a different risk profile and are often better tolerated. CBD drug interactions do exist, however - notably with anti-epileptics and anticoagulants - and medical consultation remains necessary even for CBD-dominant formulations.

 

Specialized medicine - Specialist physicians | Clinique Omicron